Literature DB >> 21953071

Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.

Orsi Giricz1, Paul A Reynolds, Andrew Ramnauth, Christina Liu, Tao Wang, Lesley Stead, Geoffrey Childs, Thomas Rohan, Nella Shapiro, Susan Fineberg, Paraic A Kenny, Olivier Loudig.   

Abstract

Invasive lobular carcinoma (ILC) of the breast, characterized by loss of E-cadherin expression, accounts for 5-15% of invasive breast cancers and it is believed to arise via a linear histological progression. Genomic studies have identified a clonal relationship between ILC and concurrent lobular carcinoma in situ (LCIS) lesions, suggesting that LCIS may be a precursor lesion. It has been shown that an LCIS diagnosis confers a 15-20% risk of progression to ILC over a lifetime. Currently no molecular test or markers can identify LCIS lesions likely to progress to ILC. Since microRNA (miRNA) expression changes have been detected in a number of other cancer types, we explored whether their dysregulation might be detected during progression from LCIS to ILC. Using the Illumina miRNA profiling platform, designed for simultaneous analysis of 470 mature miRNAs, we analysed the profiles of archived normal breast epithelium, LCIS lesions found alone, LCIS lesions concurrent with ILC, and the concurrent ILCs as a model of linear histological progression towards ILC. We identified two sets of differentially expressed miRNAs, the first set highly expressed in normal epithelium, including hsa-miR-224, -139, -10b, -450, 140, and -365, and the second set up-regulated during lobular neoplasia progression, including hsa-miR-375, -203, -425-5p, -183, -565, and -182. Using quantitative RT-PCR, we validated a trend of increasing expression for hsa-miR-375, hsa-miR-182, and hsa-miR-183 correlating with ILC progression. As we detected increased expression of hsa-miR-375 in LCIS lesions synchronous with ILC, we sought to determine whether hsa-miR-375 might induce phenotypes reminiscent of lobular neoplasia by expressing it in the MCF-10A 3D culture model of mammary acinar morphogenesis. Increased expression of hsa-miR-375 resulted in loss of cellular organization and acquisition of a hyperplastic phenotype. These data suggest that dysregulated miRNA expression contributes to lobular neoplastic progression.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953071     DOI: 10.1002/path.2978

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.

Authors:  Susanne Knoll; Katharina Fürst; Bhavani Kowtharapu; Ulf Schmitz; Stephan Marquardt; Olaf Wolkenhauer; Hubert Martin; Brigitte M Pützer
Journal:  EMBO Rep       Date:  2014-10-23       Impact factor: 8.807

2.  microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR.

Authors:  Chin-Wen Chang; Hui-Chen Wu; Mary Beth Terry; Regina M Santella
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

3.  Retrospective MicroRNA Sequencing: Complementary DNA Library Preparation Protocol Using Formalin-fixed Paraffin-embedded RNA Specimens.

Authors:  Olivier Loudig; Christina Liu; Thomas Rohan; Iddo Z Ben-Dov
Journal:  J Vis Exp       Date:  2018-05-05       Impact factor: 1.355

4.  Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas.

Authors:  Thomas Harris; Lizandra Jimenez; Nicole Kawachi; Jian-Bing Fan; Jing Chen; Tom Belbin; Andrew Ramnauth; Olivier Loudig; Christian E Keller; Richard Smith; Michael B Prystowsky; Nicolas F Schlecht; Jeffrey E Segall; Geoffrey Childs
Journal:  Am J Pathol       Date:  2012-01-09       Impact factor: 4.307

5.  Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.

Authors:  Matthias Dettmer; Aurel Perren; Holger Moch; Paul Komminoth; Yuri E Nikiforov; Marina N Nikiforova
Journal:  Thyroid       Date:  2013-09-19       Impact factor: 6.568

Review 6.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

7.  Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens.

Authors:  Adam Kotorashvili; Andrew Ramnauth; Christina Liu; Juan Lin; Kenny Ye; Ryung Kim; Rachel Hazan; Thomas Rohan; Susan Fineberg; Olivier Loudig
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

Review 8.  Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

Authors:  Eleni van Schooneveld; Hans Wildiers; Ignace Vergote; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  Breast Cancer Res       Date:  2015-02-18       Impact factor: 6.466

Review 9.  The role of microRNAs in breast cancer migration, invasion and metastasis.

Authors:  Joy Tang; Aamir Ahmad; Fazlul H Sarkar
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

10.  MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42.

Authors:  Tao-Wei Ke; Han-Lin Hsu; Yu-Hua Wu; William Tzu-Liang Chen; Ya-Wen Cheng; Chao-Wen Cheng
Journal:  Dis Markers       Date:  2014-04-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.